Kidney360GenomicsPeer-reviewed journal article
Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics
Esther LiuiD, Behram Radmanesh, Byung Ha ChungiD, Michael D. DonnaniD, Dan YiiD, Amal Dadi, Kelly D. SmithiD, Jonathan HimmelfarbiD, Mingyao LiiD, Benjamin FreedmaniD, Jennie J. LiniD
Abstract
BackgroundDNA variants in APOL1 associate with kidney disease, but the pathophysiological mechanisms remain incompletely understood. Model organisms lack the APOL1 gene, limiting the degree to which disease states can be recapitulated. Here we present single-cell RNA sequencing (scRNA-seq) of genome-edited human kidney organoids as a platform for profiling effects of APOL1 risk variants in diverse nephron cell types.\n\nMethodsWe performed footprint-free CRISPR-Cas9 genome editing of human induced pluripotent stem cells (iPSCs) to knock in APOL1 high-risk G1 variants at the native genomic locus. iPSCs were differentiated into kidney organoids, treated with vehicle, IFN-{gamma}, or the combination of IFN-{gamma} and tunicamycin, and analyzed with scRNA-seq to profile cell-specific changes in differential gene expression patterns, compared to isogenic G0 controls.\n\nResultsBoth G0 and G1 iPSCs differentiated into kidney organoids containing nephron-like structures with glomerular epithelial cells, proximal tubules, distal tubules, and endothelial cells. Organoids expressed detectable APOL1 only after exposure to IFN-{gamma}. scRNA-seq revealed cell type-specific differences in G1 organoid response to APOL1 induction. Additional stress of tunicamycin exposure led to increased glomerular epithelial cell dedifferentiation in G1 organoids.\n\nConclusionsSingle-cell transcriptomic profiling of human genome-edited kidney organoids expressing APOL1 risk variants provides a novel platform for studying the pathophysiology of APOL1-mediated kidney disease.\n\nSIGNIFICANCE STATEMENTGaps persist in our mechanistic understanding of APOL1-mediated kidney disease. The authors apply genome-edited human kidney organoids, combined with single-cell transcriptomics, to profile APOL1 risk variants at the native genomic locus in different cell types. This approach captures interferon-mediated induction of APOL1 gene expression and reveals cellular dedifferentiation after a secondary insult of endoplasmic reticulum stress. This system provides a human cellular platform to interrogate complex mechanisms and human-specific regulators underlying APOL1-mediated kidney disease.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 42
- FWCI
- 3.30
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Meta-analyses of the NEPTUNE dataset related to high and low risk FSGS and cellular APOL1 models identifies Calcium signalling, mTOR signaling and inflammation-associated pathways as operative in APOL1-mediated kidney disease.
Wasco Wruck, Chantelle Thimm, … James Adjaye·bioRxiv·Jul 31, 2026
- APOL1 kidney risk variants in glomerular diseases modeled in transgenic mice
T. Yoshida, K. Z. Latt, … J. B. Kopp·bioRxiv·Mar 27, 2023
- Modeling kidney development, disease, and plasticity with clonal expandable nephron progenitor cells and nephron organoids
Biao Huang, Zipeng Zeng, … Zhongwei Li·bioRxiv·May 25, 2023
- Towards the NMR solution Structure and the Dynamics of the C-terminal Region of APOL1 and its G1, G2 Variants with a Membrane Mimetic
S. M. Madhavan, A. L. Hansen, … M. Buck·bioRxiv·Mar 16, 2021
- Phenome-wide analysis of APOL1 risk variants reveals associations between one combination of haplotypes and multiple disease phenotypes in addition to chronic kidney disease
Walt E. Adamson, Harry A. Noyes, … Annette MacLeod·medRxiv·Feb 19, 2023
- Strong protective effect of the APOL1 p.N264K variant against G2-associated FSGS and kidney disease
Yask Gupta, David J. Friedman, … Simone Sanna‐Cherchi·Nature CommunicationsPeer-reviewed·Nov 30, 2023